evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,444 questions · 1,518 findings · 135 reviews · Infectious Diseases

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 135 · 8.9%GRADE not reported 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Linezolid vs no linezolid

Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis

It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).

1 finding from 1 review

MVA85A vs placebo

Active tuberculosis: confirmed by culture or Xpert® MTB/RIF longest reported · HIV‐positive and ‐negative adults and children

MVA85A showed no clear difference in active tuberculosis: confirmed by culture or Xpert® MTB/RIF longest… compared with placebo (moderate certainty).

1 finding from 1 review

MVA85A vs placebo

Active tuberculosis: started on tuberculosis treatment · HIV‐positive and ‐negative adults and children

MVA85A showed no clear difference in active tuberculosis: started on tuberculosis treatment compared with placebo (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Relapse · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Treatment failure · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Relapse · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Treatment failure · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis

It is very uncertain whether gatifloxacin‐containing 4‐month ATT regimens changes acquired drug resistance compared with standard 6‐month ATT regimens (very low certainty).

1 finding from 1 review